Brief: Meiragtx Announces Positive Data From Phase 1 Clinical Study Of AAV2-hAQP1 For The Treatment Of Grade 2/3 Radiation-Induced Xerostomia

MeiraGTx Holdings

13/12/2022 12:56

Dec 13 (Reuters) - MeiraGTx Holdings PLC  MGTX.O :
    * MEIRAGTX ANNOUNCES POSITIVE CLINICAL DATA FROM THE AQUAX
PHASE 1
CLINICAL STUDY OF AAV2-HAQP1 FOR THE TREATMENT OF GRADE 2/3
RADIATION-INDUCED XEROSTOMIA
    * MEIRAGTX HOLDINGS PLC - INCREASES IN WHOLE SALIVA FLOW
RATES
WERE SEEN IN BOTH UNILATERAL AND BILATERAL COHORTS
    * MEIRAGTX HOLDINGS PLC - OVERALL DEGREE OF IMPROVEMENT WAS
GREATER IN BILATERAL COMPARED TO UNILATERAL COHORTS
    * MEIRAGTX HOLDINGS PLC - AAV2-HAQP1 APPEARS SAFE AND WELL
TOLERATED AT EACH DOSE TESTED
    * MEIRAGTX HOLDINGS PLC - AAV2-HAQP1 APPEARS SAFE AND WELL
TOLERATED AT EACH DOSE TESTED
    * MEIRAGTX HOLDINGS PLC - CLINICALLY MEANINGFUL IMPROVEMENTS
IN
XEROSTOMIA SYMPTOMS AND DISEASE BURDEN REPORTED IN PATIENT
REPORTED OUTCOME MEASURES
    * MEIRAGTX HOLDINGS  - INTENDS TO INITIATE PHASE 2 STUDY
EVALUATING BILATERAL ADMINISTRATION OF TWO ACTIVE DOSES OF
AAV2-HAQP1 IN FIRST HALF OF 2023

Source text for Eikon:  ID:nGNX53rqgQ 
Further company coverage:  MGTX.O 
 ((Reuters.Briefs@thomsonreuters.com;))